(Q59793953)

21

object named as

Jeffrey Schlom

0 references

James L. Gulley

25

object named as

James L Gulley

0 references

Jane B Trepel

16

object named as

Jane B Trepel

0 references

author name string

Fatima Karzai

1

0 references

Ravi A Madan

3

0 references

Helen Owens

4

0 references

Lisa M Cordes

5

0 references

Amy Hankin

6

0 references

Anna Couvillon

7

0 references

Erin Nichols

8

0 references

Marijo Bilusic

9

0 references

Michael L Beshiri

10

0 references

Kathleen Kelly

11

0 references

Venkatesh Krishnasamy

12

0 references

Sunmin Lee

13

0 references

Min-Jung Lee

14

0 references

Akira Yuno

15

0 references

Maria J Merino

17

0 references

Ryan Dittamore

18

0 references

Jennifer Marté

19

0 references

Renee N Donahue

20

0 references

Keith J Killian

22

0 references

Paul S Meltzer

23

0 references

Seth M Steinberg

24

0 references

Jung-Min Lee

26

0 references

William L Dahut

Journal for Immunotherapy of Cancer

27

0 references

language of work or name

English

0 references

publication date

4 December 2018

0 references

published in

0 references

volume

6

0 references

issue

1

0 references

page(s)

141

0 references

copyright license

Creative Commons Attribution 4.0 International

start time

1 December 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s40425-018-0463-2

0 references

cites work

CD83 on dendritic cells: more than just a marker for maturation

1 reference

12 December 2020

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

12 December 2020

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

12 December 2020

Integrative genomics viewer

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

1 reference

12 December 2020

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

1 reference

12 December 2020

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

1 reference

12 December 2020

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

1 reference

12 December 2020

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer

1 reference

12 December 2020

The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy

1 reference

12 December 2020

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

1 reference

12 December 2020

DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity

1 reference

12 December 2020

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

1 reference

12 December 2020

Integrative clinical genomics of advanced prostate cancer

1 reference

12 December 2020

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

1 reference

12 December 2020

Lack of Impact of Robotic Assisted Laparoscopic Radical Prostatectomy on Intraoperative Levels of Prostate Cancer Circulating Tumor Cells.

1 reference

12 December 2020

STING: infection, inflammation and cancer

1 reference

12 December 2020

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

1 reference

12 December 2020

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

12 December 2020

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

1 reference

12 December 2020

Microsatellite Instability as a Biomarker for PD-1 Blockade

1 reference

12 December 2020

CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing.

1 reference

12 December 2020

A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.

1 reference

12 December 2020

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

1 reference

12 December 2020

Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing

1 reference

12 December 2020

The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinosta

1 reference

12 December 2020

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

1 reference

12 December 2020

Elements of cancer immunity and the cancer-immune set point

1 reference

12 December 2020

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.

1 reference

12 December 2020

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

1 reference

12 December 2020

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

1 reference

12 December 2020

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.

1 reference

12 December 2020

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-

1 reference

12 December 2020

Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation.

1 reference

12 December 2020

DNA Damage and Repair Biomarkers of Immunotherapy Response

1 reference

12 December 2020

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.

1 reference

12 December 2020

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.

1 reference

12 December 2020

Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

1 reference

12 December 2020

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

1 reference

12 December 2020

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

1 reference

12 December 2020

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

1 reference

12 December 2020